Restricted accessResearch articleFirst published online 1998-7
The novel buspirone analogue,8-[4-[2-(1,2,3,4-tetrahydroisoquinolinyl) [butyl]-8 -azaspiro[4.5] decane-7,9 dione,with anxiolytic-like and antidepressant-like effects in rats
In the conflict drinking test, used as a model to examine anxiolytic-like activity, the novel buspirone analogue 8- [4-[2-(1,2,3,4-tetrahydroisoquinolinyl)]butyl)-8-azaspiro[4.5]decane-7,9-dione (MM199) (0.62-2.5 mg/kg) and buspirone (0.62-5 mg/kg), significantly increased the punished drinking in water-deprived rats, without affecting water consumption or perception of the stimulus. The anticonflict activity of MM199 (1.25 mg/kg) was blocked by (S)-WAY 100135 (20 mg/kg), a 5-hydroxytrypatmine1A (5-HT1A) receptor antagonist. In the forced swimming test, used as a model to examine the antidepressant-like activity, MM199 (5-20 mg/kg) reduced the immobility time, while buspirone (5-20 mg/kg) had no such effect. The reduced immobility induced by MM199 (20 mg/kg) was antagonized by (S)-WAY100135 (10 mg/kg). The above findings suggest that MM199 possesses potent anxiolytic- and antidepressant-like properties which are mediated by activation of 5- HT1A receptors.
Abe M., Tabata R., Saito K-I., Matsuda T., Baba A., Egawa M. (1996) Novel benzodioxan derivative, 5-{3-[((2S)-1,4-benzodioxan-2-ylmethyl)amino]propoxy}-1,3-benzodioxole HCl (MKC-242), with anxiolytic-like and antidepressant-like effects in animal models. J Pharmac Exp Ther278: 898-905
2.
Amano M., Goto A., Sakai A., Achiha M., Hara N., Takahashi N., Hara C., Ogawa N. (1993) Comparison of the anticonflict effect of buspirone and its major metabolite 1-(2-pyrimidinyl)-piperazine (1-PP) in rats. Jap J Pharmac61: 311-317
3.
Berendsen H H G, Jenck F., Broekkamp C L E (1989) Selective activation of 5-HT1A receptors induces lower lip retraction in the rat. Pharmac Biochem Behav33: 821-827
4.
Bianchi G., Garattim S. (1988) Blockade of α2-adrenoceptors by 1-(2-pyrimidinyl)-piperazine (PmP) in vivo and its relation to the activity of buspirone. Eur J Pharmac147: 343-350
5.
Caccia S., Conti I., Vigano G., Garattini S. (1986) 1-(2-Pyrimidinyl)-piperazine as active metabolite of buspirone in man and rat. Pharmacology33: 46-51
6.
Caccia S., Muglia M., Mancmelli A., Garattini S. (1983) Disposition and metabolism of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in the rat. Xenobiotics13: 147-153
7.
Cervo L., Grignaschi G., Samanin R. (1988) Different effects of intracerebral and systemic administration of buspirone in the forced swimming test: involvement of a metabolite. Life Sci43: 2095-2102
8.
Chilmończyk Z., Leś A., Wozniakowska A., Cybulski J., Koziol A.E., Gdamec M. (1995) Buspirone analogues as ligands of the 5-HT 1A receptor. 1. The molecular structure of buspirone and its two analogues . J Med Chem38: 1701-1710
9.
Deakin J F W (1993) A review of clinical efficacy of 5 -HT1A agonist in anxiety and depression. J Psychopharmac7: 283-289
10.
Dourish C.T. (1987) Brain 5-HT1A receptors and anxiety. In Dourish C T, Ahlenius S, Hutson PH (eds), Brain 5-HT1A receptors. Ellis Horwood : Chichester, pp. 261-277
11.
Fletcher A., Bill D.J., Bill S.J., Cliffe I.A., Dover G.M., Forster E.A., Haskins J.T., Jones D., Mansell H.L., Reilly Y. (1993) WAY 100135: a novel, selective antagonist at presynaptic and postsynaptic 5-HT1A receptors. Eur J Pharmac237: 283-291
12.
Gammans RE, Mayol RF, Labudde JA (1986) Metabolism and disposition of buspirone. Am J Med80: 41-51
13.
Giral P., Soubrie P., Puech A.J. (1987) Pharmacological evidence for the involvement of 1-(2-pyrimidinyl)-piperazine (1-PmP) in the interaction of buspirone or gepirone with noradrenergic systems. Eur J Pharmac134: 113-116
14.
Glennon R.A., Naiman N.A., Lyon R.A., Titeler M. (1988) Arylpiperazine derivatives as high affinity 5-HT 1A serotonin ligands. J Med Chem31: 1968-1971
15.
Glennon R.A., Westkaemper R.B., Bartyzel P. (1991) Medicinal chemistry of serotonergic agents. In Peroutka SJ (ed.), Serotonin receptor subtypes: basic and clinical aspects. Wiley-Liss , New York, pp.19-64
16.
Gower AJ, Tricklebank M.D. (1988) α2-Adrenoceptor antagonist activity may account for the effects of buspirone in an anticonflict test in the rat . Eur J Pharmac155: 129-137
17.
Hascoet M., Bourin M., Todd KG, Couetoux du Tertre A. (1994) Anticonflict effect of 5-HT1A agonists in rats: a new model for evaluating anxiolytic-like activity. J Psychopharmac8: 227-237
18.
Hibert M.F., Gittos M.W., Middlemiss D.N., Mir A.K., Fozard J.R. (1988) Graphics computer-aided receptor mapping as a predictive tool for drug design: development of potent, selective, and stereospecific ligands for the 5-HT1A receptor. J Med Chem31: 1087-1093
19.
Hibert M.F., McDermott I., Middlemiss D.N., Mir A.K., Fozard J.R. (1989) Radioligand binding study of a series of 5-HT 1A receptor agonists and definition of a steric model of this site. Eur J Med Chem24: 31-37
20.
Janssen PA J, Jageneau A H M, Schellekens K H C (1960) Chemistry and pharmacology of compounds related to 4-(4-hydroxy-4-phenyl-piperidine)-butyrophenone. Part IV Influence of haloperidol (R-1625) and chloropromazine on the behaviour of rats in an unfamiliar open field situation. Psychopharmacology1: 389-392
21.
McCloskey T.C., Paul B.K., Commissaris R.L. (1987) Buspirone effects in an animal conflict procedure: comparison with diazepam and phenobarbital. Pharmac Biochem Behav27: 171-175
22.
McMillen BA, Scott SM, Williams HL, Sanghera M.K. (1987) Effects of gepirone, an aryl-piperazine anxiolytic drug, on aggressive behaviour and brain monoaminergic neurotransmission. Naunyn-Schmiedeberg's Arch Pharmac335: 454-464
23.
Mokrosz JL, Mokrosz MJ, Bojarski AJ, Charakchieva-Minol S. (1994) Structure-activity relationship studies of CNS agents. 16. A lower limit of a distance between crucial pharmacophores of 5-HT1A ligands. Pharmazie49: 781-782
Mokrosz M.J., Duszyńska B., Bojarski A.J., Mokrosz J.L. (1995b) Structure-activity relationship studies of CNS agents. 17. Spiro-[piperidine-4',1-(1,2,3,4-tetrahydro-β-carboline)] as a probe defining the extended topographic model of 5-HT1A receptorsBioorg Med Chem3: 533-538
26.
Mokrosz J.L., Dereń-Wesolek A., Tatarczyńska E., Duszyńska B., Bojarski A.J., Mokrosz M.J., Chojnacka-Wójcik E. (1996) 8-[4-[2-(1,2,3,4-Tetrahydroisoquinolinyl)]butyl]-8-azaspiro-[4.5]decane-7, 9-dione: a new 5-HT1A receptor ligand with the same activity profile as buspirone. J Med Chem39: 1125-1129
27.
Pich E.M., Samanin R. (1986) Disinhibitory effects of buspirone and low doses of sulpiride and haloperidol in two experimental anxiety models in rats: possible role of dopamine. Psychopharmacology89: 125-130
28.
Porsolt R.D., Anton G., Blavet N., Jalfre M. (1978) Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmac47: 379-391
29.
Przegaliński E., Tatarczyńska E., Chojnacka-Wójcik E. (1989) Anticonflict effect of ipsapirone, buspirone and gepirone is not mediated by their common metabolite 1-(2-pyrimidinyl)-piperazine . J Psychopharmac3: 184-185
30.
Przegaliński E., Filip M., Budziszewska B., Chojnacka-Wōjcik E. (1994) Antagonism of (+)WAY 100135 to behavioural, hypothermic and corticosterone effects induced by 8- OH-DPAT. Pol J Pharmac46: 21-27
31.
Przegaliński E.,Tatarczyńska E., Chojnacka-Wójcik E. (1990) Antidepressant-like activity of ipsapirone, buspirone and gepirone in the forced swimming test in rats pretreated with proadifen . J Psychopharmac4: 204-209
32.
Routledge C., Gurling JW, Wright I.K., Dourish C.T. (1993) Neurochemical profile of the selective and silent 5-HT1A receptor antagonist WAY 100135: an in vivo microdialysis study. Eur J Pharmac239: 195-202
33.
Smith L.M., Peroutka S.J. (1986) Differential effects of 5-hydroxytryptamine 1A selective drugs on the 5-HT behavioral syndrome. Pharmac Biochem Behav24: 1513-1519
34.
Traber J., Schuurman T., Benz U. ( 1988) A comparison of the 5-HT1A receptor-related anxiolytics buspirone, gepirone, ipsapirone, SM-3997, their common metabolite 1-PP and diazepam in animal models of anxiety. Psychopharmacology96 (Suppl.): 352
35.
Van Steen B.J., Van Wijngaarden I., Tulp M T M, Soudijn W. (1994) Structure-affinity relationship studies on 5-HT 1A receptor ligands. 2. Heterobicyclic phenylpiperazines with N4-aralkyl substituents. J Med Chem37: 2761-2773
36.
Vogel J.R., Beer B., Clody D.E. (1971) A simple and reliable conflict procedure for testing antianxiety agents. Psychopharmacologia21:1-7
37.
Willner P. (1984) The validity of animal models of depression. Psychopharmacology83: 1-16
38.
Young R., Urbancic A., Emrey TA, Hall PC, Metcalf G. (1987) Behavioral effects of several new anxiolytics and putative anxiolytics. Eur J Pharmac143: 361-371
39.
Zifa E., Fillion G. (1992) 5-Hydroxytryptamine receptors. Pharmac Rev44: 401-458
